# uniQure N.V. (QURE)

> uniQure N.V. (QURE) trades at $19.35 (-4.35%) as of 7:30:06 PM EST on Nov 20, 2026, -16.27% over the past month. Market cap is $1.36B, with 6.4 days to cover in short interest.

Canonical: https://massive.com/quote/qure
Data as of: 2026-11-21T00:30:06.364Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$19.35** -0.88 (-4.35%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$20.12** +0.77 (+3.98%)
As of 7:30:06 PM EST on Nov 20, 2026 · After hours

## Stock performance

How uniQure N.V. (QURE) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -4.35% |
| 1W | -18.73% |
| 1M | -16.27% |
| YTD | -19.14% |
| 1Y | -30.35% |
| 52-wk range | $8.73 – $51.72 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for QURE: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $19.00 – $21.60 |
| Open | $19.82 |
| Prev close | $20.23 |
| Volume | 2.1M |
| Market cap | $1.36B |
| Shares out | 70.14M |

## Valuation and profitability ratios

Valuation and profitability ratios for uniQure N.V.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 67.30 |
| P/B | 4.61 |
| P/FCF | — |
| ROE | -79.0% |
| ROA | -24.8% |
| Debt/Equity | 0.17 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[uniQure N.V. (QURE) insider trading](https://massive.com/quote/qure/insider-trading.md): open-market Form 4 buys and sells by uniQure N.V. insiders over the last 12 months.

## 8-K filings

Material corporate events uniQure N.V. has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, uniQure N.V. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update.”
- Nov 2, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  ““The BLA is supported by the previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database.””
- Sep 29, 2026 · Investor presentation
  ““On September 29, 2026, uniQure N.V. (the "Company") presented an update of its ongoing clinical trials of AMT-130 (the "Presentation") and issued a press release which summarizes the Presentation (the "Release").””
- Jun 24, 2026 · Public offering
  “On June 23, 2026, uniQure N.V. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, as representative of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 4,945,055 of the Company's ordinary shares (the "Firm Shares"), at a price to the public of $45.50 per ordinary share.”
- Jun 22, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “As of the May 29, 2026 data cutoff date, three of six patients in the first, low-dose cohort (1x1012 gc/mL) achieved meaningful reductions in disabling seizures during months four through six of follow-up, ranging from a 79% to 100% decline from baseline. The remaining three patients in the low-dose cohort experienced variable changes in disabling seizures during months four through six of follow-up, ranging from a 33% decrease to a 36% increase compared to baseline. As of June 19, 2026, there have been no serious adverse events related to AMT-260 or the surgical procedure reported. All reported adverse events in the low dose cohort were classified as mild or moderate in severity, with the most common adverse event being headache (N=2).”

## QURE short interest

How heavily QURE is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.4 |
| Short interest | 8.51M |
| Avg volume | 1.33M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## QURE news

The latest news and headlines about uniQure N.V. (QURE).

- [QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?](https://www.zacks.com/stock/news/3029783/qure-stock-rallies-17-5-in-a-month-what-should-investors-do-now?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-3029783) · Zacks Investment Research · Nov 13, 2026 · neutral sentiment
- [3 Promising Genomics Stocks to Add to Your Portfolio Now](https://www.zacks.com/stock/news/3019714/3-promising-genomics-stocks-to-add-to-your-portfolio-now?cid=CS-ZC-FT-genomics_&_synthetic_biology-3019714) · Zacks Investment Research · Oct 30, 2026 · positive sentiment
- [INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT](https://www.globenewswire.com/news-release/2026/10/13/3380255/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-clearpoint-neuro-inc-clpt.html) · GlobeNewswire Inc. · Oct 13, 2026 · negative sentiment
- [UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights](https://www.globenewswire.com/news-release/2026/09/30/3372463/937/en/uniqure-investigation-qure-securities-investors-encouraged-to-contact-kirby-mcinerney-llp-about-their-rights.html) · GlobeNewswire Inc. · Sep 30, 2026 · negative sentiment
- [uniQure Plunges on Additional Data From Huntington's Disease Study](https://www.zacks.com/stock/news/2998447/uniqure-plunges-on-additional-data-from-huntington-s-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2998447) · Zacks Investment Research · Sep 30, 2026 · negative sentiment

## About uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 221 |
| Listed | Feb 5, 2014 |

[Company website](https://www.uniqure.com)

## FAQ

### What is the uniQure N.V. (QURE) stock price today?

uniQure N.V. (QURE) is trading at $19.35 (-4.35% on the day) as of 7:30:06 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is uniQure N.V.?

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases.

### What is the short interest in QURE?

As of Oct 30, 2026, QURE has 8.51M shares short and 6.4 days to cover.

### What exchange is QURE listed on?

uniQure N.V. (QURE) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time QURE quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=QURE`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [uniQure N.V. (QURE) insider trading](https://massive.com/quote/qure/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
